Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Open access

Abstract

BACKGROUND: The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. METHODS: We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2. We randomly assigned 234 patients to receive standard chemotherapy alone and 235 patients to receive standard chemotherapy plus trastuzumab. Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide alone (138 women) or with trastuzumab (143 women). Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women). RESULTS: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression (median, 7.4 vs. 4.6 months; P<0.001), a higher rate of objective response (50 percent vs. 32 percent, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 months; P<0.001), a lower rate of death at 1 year (22 percent vs. 33 percent, P=0.008), longer survival (median survival, 25.1 vs. 20.3 months; P=0.01), and a 20 percent reduction in the risk of death. The most important adverse event was cardiac dysfunction of New York Heart Association class III or IV, which occurred in 27 percent of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 percent of the group given an anthracycline and cyclophosphamide alone; 13 percent of the group given paclitaxel and trastuzumab; and 1 percent of the group given paclitaxel alone. Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with standard medical management. CONCLUSIONS: Trastuzumab increases the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm200103153441101

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 9

  1. Press MF, 1993, Cancer Res, 53, 4960
  2. Chazin VR, 1992, Oncogene, 7, 1859
  3. Pietras RJ, 1995, Oncogene, 10, 2435
  4. Pietras RJ, 1994, Oncogene, 9, 1829
  5. Konecny G, 1999, Breast Cancer Res Treat, 57, 114
  6. Pietras RJ, 1999, Cancer Res, 59, 1347
  7. Baselga J, 1998, Cancer Res, 58, 2825
  8. Smith G, 1996, Semin Oncol, 23, 506
  9. Sledge GW, 1997, Prog Proc Am Soc Clin Oncol, 16, 1a

Cited by

See all 11,500

Metadata

Authors
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L.
Affiliations
  • University of California, Los Angeles (US)
  • McGill University (CA)
  • Genentech (US)
  • University of Washington (US)
  • Rotkreuzklinikum München (DE)
  • Rush University Medical Center (US)
  • Vall d'Hebron Hospital Universitari (ES)
  • Memorial Sloan Kettering Cancer Center (US)
Venue
New England Journal of Medicine
Published
2001-03-15
Volume
344
Issue
11
Pages
783-792
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2318605753
Cited by
11,500
References
30
Citations by year
2026: 245 · 2025: 292 · 2024: 386 · 2023: 423 · 2022: 405 · 2021: 396 · 2020: 428 · 2019: 434 · 2018: 466 · 2017: 493 · 2016: 538 · 2015: 566 · 2014: 586 · 2013: 605 · 2012: 563
FWCI
164.01
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords
metastatic breast cancer, HER2 overexpression, trastuzumab, monoclonal antibodies, HER2-targeted therapy, combination chemotherapy, anthracycline cardiotoxicity, doxorubicin, cyclophosphamide, paclitaxel, time to progression, survival, objective response, cardiac dysfunction, treatment efficacy and safety, HER2 amplification
MeSH terms
Trastuzumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Doxorubicin, Female, Heart Diseases, Humans, Middle Aged, Neoplasm Metastasis, Epirubicin, Survival Analysis, Paclitaxel, Disease Progression, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Anthracyclines, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. https://app.cochat.ai/papers/10.1056/nejm200103153441101
The paper
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L. (2001). Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine. https://doi.org/10.1056/nejm200103153441101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.